Skip to main content

Articles

Page 31 of 33

  1. Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demen...

    Authors: Rianne M van der Linde, Blossom CM Stephan, George M Savva, Tom Dening and Carol Brayne
    Citation: Alzheimer's Research & Therapy 2012 4:28
  2. Clinical research is best done when aligned with clinical care - that is, when the patient can be identified, recruited and, in many instances, researched in parallel with the delivery of clinical service. How...

    Authors: Piers Kotting, Kris Beicher, Ian G McKeith and Martin N Rossor
    Citation: Alzheimer's Research & Therapy 2012 4:23
  3. Alzheimer's disease is an age-associated, irreversible, progressive neurodegenerative disease that is characterized by severe memory loss, unusual behavior, personality changes, and a decline in cognitive func...

    Authors: Rammohan V Rao, Olivier Descamps, Varghese John and Dale E Bredesen
    Citation: Alzheimer's Research & Therapy 2012 4:22
  4. The current pathological confirmation of the diagnosis of Alzheimer's disease (AD) is still based on postmortem identification of parenchymal amyloid beta (Aβ) plaques, intra-neuronal neurofibrillary tangles, ...

    Authors: Amanda Hanna, Kayleigh Iremonger, Pritam Das, Dennis Dickson, Todd Golde and Christopher Janus
    Citation: Alzheimer's Research & Therapy 2012 4:21
  5. Neuropathological studies have revealed the presence of a broad variety of inflammation-related proteins (complement factors, acute-phase proteins, pro-inflammatory cytokines) in Alzheimer's disease (AD) brain...

    Authors: Piet Eikelenboom, Jeroen JM Hoozemans, Rob Veerhuis, Eric van Exel, Annemieke JM Rozemuller and Willem A van Gool
    Citation: Alzheimer's Research & Therapy 2012 4:15
  6. A hallmark of Alzheimer's disease (AD) is the presence of senile plaques composed of aggregated amyloid β (Aβ) peptides. Pathological aging (PA) is a postmortem classification that has been used to describe br...

    Authors: Brenda D Moore, Paramita Chakrabarty, Yona Levites, Tom L Kukar, Ann-Marie Baine, Tina Moroni, Thomas B Ladd, Pritam Das, Dennis W Dickson and Todd E Golde
    Citation: Alzheimer's Research & Therapy 2012 4:18
  7. The low-density lipoprotein receptor-related protein (LRP1) and its family members have been implicated in the pathogenesis of Alzheimer's disease. Multiple susceptibility factors converge to metabolic pathway...

    Authors: Guilian Xu, Cameron C Green, Susan E Fromholt and David R Borchelt
    Citation: Alzheimer's Research & Therapy 2012 4:12
  8. Previous work indicates that resting-state functional magnetic resonance imaging (fMRI) is sensitive to functional brain changes related to Alzheimer's disease (AD) pathology across the clinical spectrum. Cros...

    Authors: Jessica S Damoiseaux
    Citation: Alzheimer's Research & Therapy 2012 4:8
  9. Dementia, a major cause of disability and institutionalization in older people, poses a serious threat to public health and to the social and economic development of modern society. Alzheimer's disease (AD) an...

    Authors: Francesca Mangialasche, Miia Kivipelto, Alina Solomon and Laura Fratiglioni
    Citation: Alzheimer's Research & Therapy 2012 4:6
  10. Alzheimer's disease (AD) is a cognitive disorder with a number of complex neuropathologies, including, but not limited to, neurofibrillary tangles, neuritic plaques, neuronal shrinkage, hypomyelination, neuroi...

    Authors: Paul L Wood
    Citation: Alzheimer's Research & Therapy 2012 4:5
  11. Frontotemporal lobar degeneration (FTLD) is a devastating neurodegenerative disease that is the second most common form of dementia affecting individuals under age 65. The most common pathological subtype, FTL...

    Authors: Alexandra M Nicholson, Jennifer Gass, Leonard Petrucelli and Rosa Rademakers
    Citation: Alzheimer's Research & Therapy 2012 4:4
  12. Resting-state functional magnetic resonance imaging (fMRI) is emerging as an interesting biomarker for measuring connectivity of the brain in patients with Alzheimer's disease (AD). In this review, we discuss ...

    Authors: Prashanthi Vemuri, David T Jones and Clifford R Jack Jr
    Citation: Alzheimer's Research & Therapy 2012 4:2
  13. Recent epidemiologic studies have noted that risk factors for atherosclerosis (for example, diabetes mellitus, hypertension, and hyperlipidemia) are associated with increased risk of incident Alzheimer's disea...

    Authors: Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters and Wendy J Mack
    Citation: Alzheimer's Research & Therapy 2012 3:1
  14. Although the molecular mechanisms underlying the pathogenesis of Alzheimer's disease and other related neurodegenerative diseases remain unclear, accumulation of misfolded proteins, neuroinflammation, mitochon...

    Authors: Rachel F Lane, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2011 3:36
  15. Patient-reported outcome (PRO) measures are used to evaluate disease and treatments in many therapeutic areas, capturing relevant aspects of the disorder not obtainable through clinician or informant report, i...

    Authors: Lori Frank, William R Lenderking, Kellee Howard and Marc Cantillon
    Citation: Alzheimer's Research & Therapy 2011 3:35
  16. Because the pathologic processes that underlie Alzheimer's disease (AD) appear to start 10 to 20 years before symptoms develop, there is currently intense interest in developing techniques to accurately predic...

    Authors: Deborah E Barnes and Sei J Lee
    Citation: Alzheimer's Research & Therapy 2011 3:33
  17. With the recent publication of new criteria for the diagnosis of preclinical Alzheimer's disease (AD), there is a need for neuropsychological tools that take premorbid functioning into account in order to dete...

    Authors: Steven D Shirk, Meghan B Mitchell, Lynn W Shaughnessy, Janet C Sherman, Joseph J Locascio, Sandra Weintraub and Alireza Atri
    Citation: Alzheimer's Research & Therapy 2011 3:32
  18. Animal models have contributed significantly to our understanding of the underlying biological mechanisms of Alzheimer's disease (AD). As a result, over 300 interventions have been investigated and reported to...

    Authors: Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney…
    Citation: Alzheimer's Research & Therapy 2011 3:28
  19. Patients with mild cognitive impairment are at an increased risk of progression to Alzheimer's disease. However, not all patients with mild cognitive impairment progress, and it is difficult to accurately iden...

    Authors: Rik Ossenkoppele, Bart NM van Berckel and Niels D Prins
    Citation: Alzheimer's Research & Therapy 2011 3:26
  20. The Relevant Outcome Scale for Alzheimer's Disease (ROSA) is a new observer rating instrument recently developed for routine medical practice. The validity and reliability of ROSA as well as sensitivity to cha...

    Authors: Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg and Frank Tennigkeit
    Citation: Alzheimer's Research & Therapy 2011 3:27
  21. [11C]Pittsburgh Compound B positron emission tomography has now been extensively used to evaluate the amyloid load in different types of dementia and has become a powerful research tool in the field of neurodegen...

    Authors: Paul Edison, Rainer Hinz and David J Brooks
    Citation: Alzheimer's Research & Therapy 2011 3:25
  22. Alzheimer's disease (AD) therapies are increasingly being tested in global clinical trials. A search of ClincalTrials.gov revealed that of 269 currently active trials, 28% are currently being conducted in the ...

    Authors: Jeffrey Cummings, Robert Reynders and Kate Zhong
    Citation: Alzheimer's Research & Therapy 2011 3:24
  23. The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibito...

    Authors: Carina Wattmo, Åsa K Wallin, Elisabet Londos and Lennart Minthon
    Citation: Alzheimer's Research & Therapy 2011 3:23
  24. Progressive language impairment is among the primary components of cognitive decline in Alzheimer's disease (AD). Because expressive and receptive language help to maintain emotional connections to caregivers ...

    Authors: Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun and Yikang Xu
    Citation: Alzheimer's Research & Therapy 2011 3:22
  25. The pathology of Alzheimer's disease (AD) is characterized by amyloid plaques (aggregates of amyloid-β (Aβ)) and neurofibrillary tangles (aggregates of tau) and is accompanied by mitochondrial dysfunction, but...

    Authors: Anne Eckert, Karen Schmitt and Jürgen Götz
    Citation: Alzheimer's Research & Therapy 2011 3:15
  26. Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's perme...

    Authors: François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy and Olivier Hermine
    Citation: Alzheimer's Research & Therapy 2011 3:16
  27. The clinical and scientific study of dementia in adults with Down syndrome led to the development of the amyloid hypothesis as a fundamental concept in Alzheimer's disease pathogenesis. The journey started wit...

    Authors: Robyn A Wallace and Arthur J Dalton
    Citation: Alzheimer's Research & Therapy 2011 3:13
  28. APOE is the strongest risk gene for sporadic Alzheimer's disease (AD) so far. Recent genome wide association studies found links for sporadic AD with CLU and CR1 involved in Aβ clearance, and PICALM affecting int...

    Authors: Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo and Pekka J Karhunen
    Citation: Alzheimer's Research & Therapy 2011 3:12